Literature DB >> 11305749

Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis.

P Sarchielli1, G P Pelliccioli, R Tarducci, P Chiarini, O Presciutti, G Gobbi, V Gallai.   

Abstract

We aimed to increase confidence in the combined use of MRI and proton MR spectroscopy (1H-MRS) in diagnosis of amyotrophic lateral sclerosis (ALS). We investigated 12 patients with ALS, seven definite and five probable, taking into account clinical measures of motor neuron function. On T2-weighted images we found high signal in the corticospinal tract in six and low signal in the primary motor cortex in seven of the 12 patients. Atrophy of the precentral gyrus was apparent in all the patients apart from one with probable ALS. Absolute quantification of cerebral metabolites using 1H-MRS demonstrated a significantly lower mean concentration of N-acetylaspartate (NAA) in the precentral gyrus of patients with probable and definite ALS (8.5 +/- 0.62) than in control subjects (10.4 +/- 0.71; P < 0.001). NAA concentration in primary motor cortex correlated with Norris scale scores (r = 0.30; P < 0.0001) but not with the ALS Functional Rating Scale score or disease duration. Significantly lower levels of NAA were detected in patients with low signal in the motor cortex than in those without (P < 0.01). Mean choline (Cho) and creatine (Cr) values did not differ between patients with ALS and controls.

Entities:  

Mesh:

Year:  2001        PMID: 11305749     DOI: 10.1007/s002340000472

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  23 in total

Review 1.  The present and the future of neuroimaging in amyotrophic lateral sclerosis.

Authors:  F Agosta; A Chiò; M Cosottini; N De Stefano; A Falini; M Mascalchi; M A Rocca; V Silani; G Tedeschi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

2.  Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Authors:  Hongxia Lei; Elisabeth Dirren; Carole Poitry-Yamate; Bernard L Schneider; Rolf Gruetter; Patrick Aebischer
Journal:  J Cereb Blood Flow Metab       Date:  2018-02-05       Impact factor: 6.200

Review 3.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

Review 4.  MR imaging findings in hepatic encephalopathy.

Authors:  A Rovira; J Alonso; J Córdoba
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

5.  Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS.

Authors:  J D Carew; G Nair; P M Andersen; J Wuu; S Gronka; X Hu; M Benatar
Journal:  Neurology       Date:  2011-09-21       Impact factor: 9.910

6.  Proton magnetic resonance spectroscopy in patients with early stages of amyotrophic lateral sclerosis.

Authors:  Stefan Sivák; Michal Bittšanský; Egon Kurča; Monika Turčanová-Koprušáková; Milan Grofik; Vladimír Nosál'; Hubert Poláček; Dušan Dobrota
Journal:  Neuroradiology       Date:  2010-04-06       Impact factor: 2.804

7.  Cerebral degeneration predicts survival in amyotrophic lateral sclerosis.

Authors:  S Kalra; A Vitale; N R Cashman; A Genge; D L Arnold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-07-11       Impact factor: 10.154

8.  Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.

Authors:  S G Mueller; N Schuff; M W Weiner
Journal:  NMR Biomed       Date:  2006-10       Impact factor: 4.044

Review 9.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 10.  25 years of neuroimaging in amyotrophic lateral sclerosis.

Authors:  Bradley R Foerster; Robert C Welsh; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2013-08-06       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.